We are monitoring the impact of COVID-19 on North America Cancer Vaccines Market Get in touch with us for detailed analysis Know More
Pulished Date April, 2021
ID: 1344
Share on
Share on

North America Cancer Vaccines Market Research Report – Segmented By Treatment Type, Cancer Type, Vaccine Type, End-User and Region (the United States, Canada and Rest of North America) - Industry Analysis, Size, Share, Growth, Trends, and Forecast (2021 to 2026)

Pulished: April, 2021
ID: 1344
Pages: 145

North America Cancer Vaccines Market Size (2021 to 2026)

The size of the North America Cancer Vaccines Market was worth USD 1.73 billion in 2021 and is estimated to reach USD 3.80 billion by the end of 2026, with a growing potential of 17.03%. North America dominated the market by holding the highest shares and revenue for cancer vaccines. It is due to an increase in the number of cancer cases, rising key players and investors for vaccines, increased technology and developments, increased research, and development activities. The number of deaths and deceased ratio due to cancers are recorded more in Canada and the United States. It brings scope for new vaccine production and more research activities. Government initiatives regarding creating awareness in people for early detection of disease and treating time are a market growth factor in North America.  

Vaccines, which are also known as vaccinations, help the body to fight against the disease. Vaccines make the immune system strong that it can recognize and destroy harmful substances.

The primary factor which significantly boosting the growth of the cancer vaccines market in North America is the increasing prevalence of the geriatric population and rising population with chronic diseases. The growing popularity of effective alternative solutions in place of therapies among the people contributes to the growth of the North America Cancer Vaccines market. Increasing demand for novel and effective vaccines due to the continually growing incidence of cancer is catalyzing the growth of the North American market. Also, high costs associated with therapies and the increasing focus of healthcare organizations for research and development of better alternatives for cancer treatment are boosting the North America Cancer Vaccines market.

Stringent regulations pose a significant problem, limiting the growth of the North America Cancer Vaccines business. Manufacturers are hesitant to develop new vaccines due to time taking approval procedures and stringent policies of the FDA, which are opposing the market's growth and are likely to pose a challenge for the key players during the forecast period. 

The presence of prominent drug developing companies is expected to create lucrative opportunities for stakeholders in the Cancer Vaccines market in North America during the outlook period. Increasing demand for novel and useful cancer treatment alternatives among people leads to intensive research and development operations in the region. It is anticipated to offer several growth opportunities or the stakeholders in the North America cancer vaccines business. Steadily increasing geriatric population and rising incidence of chronic diseases due to biological and social factors offer lucrative growth opportunities for the key players in the cancer vaccines market in North America.

This research report on the North America Cancer Vaccines Market has been segmented & sub-segmented into the following categories:

By Cancer Type: 

  • Prostate
  • Cervical
  • Colorectal
  • Throat
  • Others

By Vaccine Type: 

  • Protein
  • Peptide-based
  • Tumor cell
  • Dendritic cell
  • Genetic vaccines
  • Others

By End User: 

  • Cancer Treatment Centres
  • Research Institutes

By Country: 

  • The United States
  • Canada
  • Rest of North America

Regionally, North America secures first place in medical care and infrastructure. Also, research and development activities are performed throughout the year. It is achieved due to awareness of a healthy lifestyle and early detection of diseases and their treatment. The public participation in vaccine trials as healthy volunteers is more growth driving factor in this market. The increase in the number of cancer cases, rising key players, and investors for vaccines' production increase market size. Technology and developments also increase cancer vaccines market growth. The prevalence of cancer cases is kept on growing so far in North America, and hence it needs more vaccine trails and new vaccines for a different type of vaccine. According to the American cancer society of cancer causes more deaths in Canada, followed by the United States. Around 1.9 million cases and 693,000 deaths were recorded in recent times.

Companies playing a promising role in the North American cancer vaccines market are Dendreon, GlaxoSmithKline, and Merck. Other companies whose products are in the pipeline stage are Aduro Biotech, Advantagene, Advaxis, Agenus, Altor BioScience, Argos Therapeutics, AVAX Technologies, Bavarian Nordic, Biothera, Celldex Therapeutics, CureVac, Galena Biopharma, Genexine, GlobeImmune, Gradalis, Heat Biologics, Immatics, ImmunoCellular Therapeutics, Inovio Pharmaceuticals, ISA Pharmaceuticals, Juvaris Biotherapeutics, NewLink Genetics, Northwest Biotherapeutics, NovaRx, OncoThyreon, Oncovir, Oxford BioMedica, Prima BioMed, Sotio, Transgene, Ubivac, Vaccinogen, and Vaxon Biotech

1.Introduction                                  

                1.1 Market Definition                    

                1.2 Study Deliverables                  

                1.3 Base Currency, Base Year and Forecast Periods                           

                1.4 General Study Assumptions                

2. Research Methodology                                           

                2.1 Introduction                              

                2.2 Research Phases                      

                                2.2.1 Secondary Research            

                                2.2.2 Primary Research 

                                2.2.3 Econometric Modelling     

                                2.2.4 Expert Validation  

                2.3 Analysis Design                         

                2.4 Study Timeline                          

3. Overview                                      

                3.1 Executive Summary                

                3.2 Key Inferences                         

                3.3 Epidemology Data                   

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                      

                4.1 Market Drivers                          

                4.2 Market Restraints                    

                4.3 Key Challenges                         

                4.4 Current Opportunities in the Market               

5. Market Segmentation                                              

                5.1 Treatment type                        

                                5.1.1 Prophylactic           

                                5.1.2 Therapeutic            

                                5.1.3 Y-o-Y Growth Analysis, By Cancer Type       

                                5.1.4 Market Attractiveness Analysis, By Cancer type      

                                5.1.5 Market Share Analysis, By Cancer Type       

                5.2 Cancer Type               

                                5.2.1 Introduction           

                                5.2.2 Prostate Cancer    

                                5.2.3 Cervical Cancer     

                                5.2.4 Colorectal Cancer 

                                5.2.5 Throat Cancer        

                                5.2.6 Others      

                                5.2.7 Y-o-Y Growth Analysis, By Cancer Type       

                                5.2.8 Market Attractiveness Analysis, By Cancer type      

                                5.2.9 Market Share Analysis, By Cancer Type       

                5.3 Vaccine Type                             

                                5.3.1 Introduction           

                                5.3.2 Tumour cell Vaccines          

                                5.3.3 Protein or Peptide Vaccines            

                                5.3.4 Genetic Vaccines  

                                                5.3.4.1 DNA Vaccines

                                                5.3.4.2 RNA Vaccines

                                5.3.5 Dendritic cell Vaccines       

                                5.3.6 other Vaccines      

                                5.3.7 Y-o-Y Growth Analysis, By Vaccine Type     

                                5.3.8 Market Attractiveness Analysis, By Vaccine Type    

                                5.3.9 Market Share Analysis, By Vaccine Type     

                5.4 End Users                   

                                5.4.1 Introduction           

                                5.4.2 Cancer Treatment Centers

                                5.4.3 Research Institutes             

                                5.4.4 Y-o-Y Growth Analysis, By End User              

                                5.4.5 Market Attractiveness Analysis, By End User            

                                5.4.6 Market Share Analysis, By End User             

6. Geographical Analysis                                              

                6.1 Introduction                              

                                6.1.1 Regional Trends    

                                6.1.2 Impact Analysis     

                                6.1.3 Y-o-Y Growth Analysis        

                                                6.1.3.1 By Geographical Area

                                                6.1.3.2 By Treatment Type

                                                6.1.3.3 By Cancer Type

                                                6.1.3.4 By Vaccine Type

                                                6.1.3.5 By End User

                                6.1.4 Market Attractiveness Analysis      

                                                6.1.4.1 By Geographical Area

                                                6.1.4.2 By Treatment Type

                                                6.1.4.3 By Cancer Type

                                                6.1.4.4 By Vaccine Type

                                                6.1.4.5 By End User

                                6.1.5 Market Share Analysis        

                                                6.1.5.1 By Geographical Area

                                                6.1.5.2 By Treatment Type

                                                6.1.5.3 By Cancer Type

                                                6.1.5.4 By Vaccine Type

                                                6.1.5.5 By End User

                6.2 United States                            

                6.3 Canada                         

7.Strategic Analysis                                        

                7.1 PESTLE analysis                         

                                7.1.1 Political     

                                7.1.2 Economic 

                                7.1.3 Social         

                                7.1.4 Technological         

                                7.1.5 Legal          

                                7.1.6 Environmental      

                7.2 Porter’s Five analysis                              

                                7.2.1 Bargaining Power of Suppliers        

                                7.2.2 Bargaining Power of Consumers    

                                7.2.3 Threat of New Entrants     

                                7.2.4 Threat of Substitute Products and Services

                                7.2.5 Competitive Rivalry within the Industry      

8.Market Leaders' Analysis                                          

                8.1 Merck & co                 

                                8.1.1 Overview

                                8.1.2 Product Analysis   

                                8.1.3 Financial analysis  

                                8.1.4 Recent Developments       

                                8.1.5 SWOT analysis       

                                8.1.6 Analyst View          

                8.2 Dendreon                   

                8.3 Glaxosmithkline                       

                8.4 AstraZeneca plc                        

                8.5 Aduro BioTech                          

                8.6 MedImmune                             

                8.7 Sanofi                           

                8.8 Galena Biopharma                   

                8.9 Ubivac                          

                8.10 Oxford Biomedica                 

                8.11 Immunofrontier Inc                              

                8.12 Oncovir Inc                               

                8.13 Immune Cell Therapy (ICT)                

9.Competitive Landscape                                            

                9.1 Market share analysis                            

                9.2 Merger and Acquisition Analysis                        

                9.3 Agreements, collaborations and Joint Ventures                          

                9.4 New Product Launches                          

10.Market Outlook and Investment Opportunities                                           

Appendix                                           

                a) List of Tables                

                b) List of Figures                              

  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
  1. North America Cancer Vaccines Market, By Treatment Type, From 2021 to 2026 (USD Billion)
  2. North America Prophylactic Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  3. North America Therapeutic Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  4. North America Cancer Vaccines Market, By Cancer Type, From 2021 to 2026 (USD Billion)
  5. North America Prostate Cancer Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  6. North America Cervical Cancer Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  7. North America Colorectal Cancer Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  8. North America Throat Cancer Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  9. North America Cancer Vaccines Market, By Vaccine Type, From 2021 to 2026 (USD Billion)
  10. North America Tumour cell Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  11. North America Protein or Peptide Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  12. North America Genetic Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  13. North America Dendritic cell Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  14. North America Cancer Vaccines Market, By End User, From 2021 to 2026 (USD Billion)
  15. North America Cancer Treatment Centers' Vaccine Usage Market, By Region, From 2021 to 2026 (USD Billion)
  16. North America Research Institutes' Vaccine Usage Market, By Region, From 2021 to 2026 (USD Billion)
  17. United States Cancer Vaccines Market, By Treatment Type, From 2021 to 2026 (USD Billion)
  18. United States Cancer Vaccines Market, By Cancer Type, From 2021 to 2026 (USD Billion)
  19. United States Cancer Vaccines Market, By Vaccine Type, From 2021 to 2026 (USD Billion)
  20. United States Cancer Vaccines Market, By End User, From 2021 to 2026 (USD Billion)
  21. Canada Cancer Vaccines Market, By Treatment Type, From 2021 to 2026 (USD Billion)
  22. Canada Cancer Vaccines Market, By Cancer Type, From 2021 to 2026 (USD Billion)
  23. Canada Cancer Vaccines Market, By Vaccine Type, From 2021 to 2026 (USD Billion)
  24. Canada Cancer Vaccines Market, By End User, From 2021 to 2026 (USD Billion)

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 3335

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample